SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Inclusion Criteria: * Male and female aged between 20 and 85 years. * Patients fulfilling one of the following diagnosis: * Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds. * Five patients with proven genetic diagnosis of CMT1a or CMT1b * Five patients with anti-MAG polyneuropathy. * Electrophysiological parameters worsening for the past 3 years * Available EMG record, performed during the past 6 months to assess variability of NCV parameters * Signed and dated written informed consent to participate in the study in accordance with local regulations * Likely to be able to participate in all scheduled evaluation and complete all required study procedures, * In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study. * Both male and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel) must commit to using TWO highly effective method of birth control for the duration of the study and for two months after the treatment termination. Exclusion Criteria: * Any general chronic handicapping disease other than peripheral neuropathy * Impossibility to perform the 10 meters walking test * Impossibility to assess electrophysiological parameters * Patients with uncontrolled hepatic disord…